UK markets closed

ACADIA Pharmaceuticals Inc. (ACAD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
15.76+0.42 (+2.74%)
At close: 04:00PM EST
15.76 0.00 (0.00%)
After hours: 04:56PM EST

ACADIA Pharmaceuticals Inc.

12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
858 558 2871

Full-time employees510

Key executives

NameTitlePayExercisedYear born
Mr. Stephen R. Davis J.D.CEO & Director1.03MN/A1961
Dr. Srdjan R. Stankovic M.D., M.S.P.H.Pres933.1k2.04M1957
Mr. Mark C. SchneyerExec. VP & CFO555.49kN/A1974
Mr. Brendan P. TeehanExec. VP, COO & Head of Commercial486.47kN/A1969
Mr. Austin D. KimExec. VP, Gen. Counsel & Sec.559.24kN/A1964
Mr. James K. KiharaVP, Chief Accounting Officer & Corp. ControllerN/AN/A1981
Mr. Bob MischlerSr. VP of Strategy & Technology OperationsN/AN/AN/A
Mr. Mark C. JohnsonVP of Investor RelationsN/AN/AN/A
Ms. Julie FisherSr. VP of Marketing & Commercial StrategyN/AN/AN/A
Ms. Holly ValdiviezSr. VP & Head of SalesN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Corporate governance

ACADIA Pharmaceuticals Inc.’s ISS governance QualityScore as of 28 November 2022 is 6. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.